Further investigation of ATRA-induced translatome revealed the abnormal activation of PI3K/AKT during ATRA treatment, and we then advised a sequential strategy containing ATRA plus a PI3K/AKT inhibitor for AML therapy. The gene discussed is AKT1; the disease is acute myeloid leukemia.